Alnylam Pharma (ALNY) Tops Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
August 2, 2018 8:00 AM EDTReceived Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11 PDUFA Date in U.S.
Achieved Robust Enrollment in ENVISION Phase 3 Study of Givosiran and On Track to Report Topline Results from Interim Analysis for Potential Accelerated Approval
Achieved Regulatory Alignment for Phase 3 Studies of Lumasiran and ALN-TTRsc02
Maintained Strong Balance Sheet with $1.48 Billion in Cash and Expects to End 2018 with Approximately $1.0 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
